FDA 483 - SpecGx, LLC - January 17, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
SpecGx LLC in Hobart, NY, was cited for significant deficiencies across four observations during an FDA inspection. The firm failed to control microbiological quality of raw materials, exhibited poor laboratory control mechanisms including dissolution apparatus issues and cross-contamination risks, and lacked adequate air pressure control in production rooms. Additionally, the company's cleaning validation methods for equipment were found to be unvalidated for microbial recovery, indicating a systemic issue with contamination prevention.
ID · d7d203b9-784e-4b98-9ae8-31b97da113e4